#USA #Irvine #Klotho Neurosciences #Joseph Sinkule #NASDAQ:KLTO

Klotho Neurosciences CEO to Attend Inaugural Conference & Scientific Seminar

On September 15-16, 2025, Dr. Joseph Sinkule, the CEO and Chairman of Klotho Neurosciences, will participate in a pivotal event: the inaugural Klotho Conference and Scientific Seminar at the Beal Applied Innovation Center of UC-Irvine in California. This highly anticipated conference is set to spotlight the potential of Klotho-based therapeutics aimed at treating neurodegenerative diseases such as ALS, Alzheimer’s, and other age-related disorders.

Pioneering Research in Neurodegeneration

The conference not only serves as a platform for Dr. Sinkule but will also feature presentations from the company’s key scientific advisors, Dr. Miguel Chillon and Dr. Assumpcio Bosch. Both scientists will share their recent breakthroughs regarding Klotho gene therapy, showcasing their innovative research on the treatment possibilities for ALS and the pursuit of longevity. This blend of leadership insights and scientific achievement reflects Klotho Neurosciences' ongoing commitment to advancing biotechnological solutions in healthcare.

Engaging Investors and Collaborators

Another significant aspect of the event is Dr. Sinkule's availability for meetings with investors and potential collaborators during the conference. Stakeholders interested in Klotho’s pioneering work can reach out to the company in advance to schedule discussions. This initiative underscores the company’s openness to partnerships aimed at furthering the development of its Klotho-based therapies, which hold promise for transforming the landscape of neurodegenerative therapies.

About Klotho Neurosciences, Inc.

Klotho Neurosciences has been at the forefront of biogenetics, focusing on innovative solutions that modify disease mechanisms through breakthroughs in cell and gene therapy. Their work utilizes a unique protein derived from the human Klotho gene, a protein associated with anti-aging properties. The company is dedicated to creating transformative treatments for neurodegenerative disorders such as ALS and Alzheimer’s disease, utilizing a proprietary delivery system that enhances the efficacy of its therapies.

Their portfolio currently includes advanced cell and gene therapy programs that leverage both DNA and RNA as therapeutic platforms, as well as genomics-based diagnostic tools. The firm’s team is composed of seasoned professionals with extensive experience in biopharmaceutical product development and commercialization, positioning Klotho Neurosciences as a significant player in the biotech industry.

The Future of Neurotherapeutics

As Klotho Neurosciences moves forward, the information shared at this conference could mark a crucial milestone in their journey towards offering innovative solutions in neurohealth. The insights gathered will not just empower Klotho but also aim to create a positive impact on the wider biotech community, paving the way for groundbreaking treatments for some of the most challenging neurodegenerative diseases we face today.

Looking Ahead

Through this conference, Klotho Neurosciences hopes to reinforce its presence in the biopharmaceutical space. The knowledge shared and connections made could potentially inspire new collaborations that further their mission in combating age-related disorders, fostering hope for millions battling neurodegenerative diseases. Given the high stakes of the race toward effective therapies, the future looks promising as Klotho takes significant strides towards its goals.

For more information, investors and interested parties can visit Klotho Neurosciences' official website or reach out via email for inquiries regarding partnerships or potential investments.